17 results about "Salbutamol" patented technology

Disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant. Particularly, disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant HFA-152a and / or HFO-1234ze(E). Also disclosed processes of preparing such compositions.

The application discloses a method for detecting clenbuterol based on thin layer chromatography and surface enhanced resonance Raman spectroscopy, and belongs to the technical field of food detection. The method comprises the following steps: (1) adopting thin layer chromatography to preliminarily separate the clenbuterol component from the matrix in the pig liver sample, and confirming the clenbuterol component in the pig liver sample under the ultraviolet lamp of 254 nm; (2) adding aromatic diazonium salt solution to the same Rf value of the clenbuterol component reference sample spot to generate azo compounds, and then adding a surface enhancer silver sol; (3) in-situ detecting the surface enhanced resonance Raman spectrum of the corresponding azo compound component spot, and if the surface enhanced resonance Raman spectrum of the pig liver sample solution at the same Rf value is the same as that of the reference sample solution, it is determined that the pig liver sample contains the clenbuterol component. The application has high specificity for detecting clenbuterol and salbutamol, high sensitivity, fast analysis speed, and is beneficial to fast detection of grass-roots units. The application is suitable for detecting clenbuterol.

The utility model discloses a salbutamol fluorescent quantitative detection card which comprises a detection card main shell, a test paper mounting groove is formed in the detection card main shell, a detection card end block is detachably mounted at one end of the detection card main shell, and extrusion buttons are slidably mounted on the upper surface and the lower surface of the detection card end block. A connecting spring is fixed between the two extrusion buttons, a test paper clamping groove is formed in the end face, facing the detection card main shell, of the detection card end block, and two anti-falling elastic clamping plates which are symmetrical up and down are fixedly arranged on the inner side of the test paper clamping groove. According to the utility model, by pressing the two extrusion buttons, the two extrusion plates extrude the two anti-drop elastic clamping plates, so that the anti-drop elastic clamping plates are separated from the detection card main shell, and the used test paper can be taken out from the detection card main shell by pulling the detection card end block, so that the detection test paper is convenient to replace; the use cost is reduced.

The present disclosure relates to an inhalation treatment device comprising: a sensor (47) configured to detect a flow parameter of a flow in a flow path (7); a controller (18) configured to conclude at least an inhalation phase and / or an exhalation phase of the user based on the output of the sensor (47), and to repeatedly operate the actuator (6) during a period of inhalation phase and not to operate the actuator (6) during a period of exhalation phase during a single treatment time, when using a test solution of salbutamol dissolved in 0.9% sodium chloride at a concentration of 0.1% (M / V) as a liquid, the aerosol output rate of the inhalation treatment device at the first opening (8) during a single treatment time is at least 0.48 g / min at the median mass diameter of the aerosol droplet of between 4.5 [mu] m and 5.0 [mu] m, and the aerosol output rate at the second opening (8) is at least 0.48 g / min at the median mass diameter of the aerosol droplet of between 4.5 [mu] m and 5.0 [mu] m. Or at least 0.42 g / min at a mass median diameter of the aerosol droplet between 4.0 [mu] m and 4.5 [mu] m, or at least 0.29 g / min at a mass median diameter of the aerosol droplet between 3.5 [mu] m and 4.0 [mu] m, or at least 0.20 g / min at a mass median diameter of the aerosol droplet between 3.0 [mu] m and 3.5 [mu] m, or at least 0.13 g / min at a mass median diameter of the aerosol droplet between 2.5 [mu] m and 3.0 [mu] m.

Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a carrier and at least one medicinally active compound, said carrier comprising at least 1234ze(E), ethanol and polyethylene glycol.

The present invention relates to a pharmaceutical composition consisting of an active ingredient based on salbutamol (a), 1,1-difluoroethane (b), a polyethylene glycol (c) and ethanol (d).The invention also relates to the use of such a pharmaceutical composition in the treatment of respiratory disorders, to a canister comprising it as well as to a metered-dose inhaler provided with such a canister.Finally, the invention relates to the uses of this pharmaceutical composition and of this canister in a metered-dose inhaler.

Disclosed is a pharmaceutical composition comprising: an active pharmaceutical ingredient (API) comprising salbutamol; from about 85% to about 99% by weight of HFO-1234ze (E); from 1% to about 15% by weight of ethanol; and greater than 0.01% to less than 0.1% by weight of oleic acid.

The invention relates to a method for preparing (R)-salbutamol. Specifically, L-threonine and a compound 1 are taken as raw materials, a compound 2 is formed under the catalysis of L-threonine transaldolase, the compound 2 is formed into a compound 3 under the catalysis of decarboxylase, on the basis, the compound 3 is taken as a substrate, and the (R)-salbutamol is further synthesized. And the method has the characteristics of low cost of raw materials and auxiliary materials, short process steps, simplicity and convenience in operation, mild reaction conditions and environmental friendliness.

A pharmaceutical composition in the form of droplets for oral administration is disclosed. The pharmaceutical composition is an aqueous solution comprising sodium chloride in an amount of 0.6% to 3% by weight per volume, at least one active ingredient selected from naloxone, yohimbine, albuterol, epinephrine, buprenorphine, and exosomes in an amount of 0.01% to 25% by weight per volume, and having a pH from 3 to 7.5. The composition is converted into droplets with diameters of 0.5 to 5 microns using an atomizer with a vibrating mesh membrane undergoing piezoelectric vibration at a frequency of 25 to 400 kilohertz. The process involves providing the composition in a capsule, inserting the capsule into the atomizer, and activating the atomizer to produce droplets. This system provides precise, efficient, and patient-friendly oral delivery of medications.

The invention discloses a method for detecting an intermediate III in a salbutamol bulk drug. The method has high system applicability, has incomparable advantages in specificity, quantitation limit, detection limit, linear range, repeatability and durability, and has high precision.

The application provides a high-sensitivity detection method for multi-residues of veterinary drugs in pig urine, and belongs to the technical field of detection of veterinary drug residues. The application first performs enzymatic treatment on the sample to be detected, thereby improving the detection sensitivity of salbutamol and ractopamine; then performs acid hydrolysis and derivatization treatment on the sample to be detected, thereby improving the reversed-phase chromatographic retention performance and mass spectrometry ionization efficiency of nitrofurans in the compound to be detected, improving the sensitivity, improving the polarity of the compound to be detected, thereby improving the chromatographic separation effect, effectively separating the interfering substances in the matrix, improving the anti-interference ability of the detected substance, and indirectly improving the detection sensitivity; clenbuterol, metronidazole, dimetridazole, olaquindox, chlorpromazine and chloramphenicol are mainly in free state, and are not affected by enzymatic and acid hydrolysis and derivatization during detection, can be detected together with the above-mentioned compounds to be detected, and the mass spectrometry derivatization and sensitivity detection of multi-residues of cross-class veterinary drugs are realized.

The invention provides a synthesis method of salbutamol, which takes p-hydroxy benzaldehyde as an initial raw material, and salbutamol is obtained through multi-step reaction. The synthesis route is simple, the cost is low, the yield and the purity are high, aftertreatment is simple, and the method is suitable for industrial production.

The present invention relates to a transdermal composition comprising a compound selected from the group comprising formoterol, salbutamol, salmeterol, fenoterol, mixtures thereof or salts thereof, and dimethylsulfoxide. The present invention further relates to a composition comprising a compound selected from the group comprising salbutamol, clenbuterol or salts thereof, and comprising at least one of water or a monohydric alcohol.

The application provides a synthesis method of levalbuterol hydrochloride, which creatively takes raw material-1 (2-[benzyl(tert-butyl)amino]-1-(2,2-dimethyl-4 H -benzo[ d ][1,3]dioxin-6-yl)ethanone) as a starting material, and high-purity levalbuterol hydrochloride is prepared through reduction, separation, hydrolysis, hydrogenation debenzylization and salt formation reaction in sequence. The method has the advantages of mild reaction, simple operation, high yield, low cost and suitability for industrial production. The levalbuterol hydrochloride prepared by the method has single impurity less than 0.05% and total impurity less than 0.1%, which can effectively ensure the safety of patients in medication.

Disclosed are pharmaceutical compositions comprising a vehicle comprising at least 1234ze(E) and ethanol and at least one pharmaceutically active compound, and devices, methods, and systems using the same.

The invention discloses a preparation method of a salbutamol EP impurity N. The salbutamol EP impurity N is obtained by taking salbutamol as a raw material and carrying out dimerization reaction under an acidic condition. The method has the advantages that the salbutamol dimer can be obtained only by one step through the dimerization reaction under the acidic condition, and multi-step complex synthesis is not needed. According to the present invention, the reaction conditions are simple, the whole process is easy to operate, the technical and operation difficulty in the synthesis process is reduced, and the synthesized and identified salbutamol EP impurity N can be adopted as the impurity reference substance, can be directly applied to the quality control link in the salbutamol bulk drug production process, and can assist the improvement of the accuracy and the reliability of the bulk drug quality research.

Pressurised dispensing container (10) comprising a container for product to be dispensed, and a valve fixed to the container; wherein the valve comprises a valve stem (15), a valve body (16) and one or more seals (20, 21), the valve stem being slidable within the valve body, the one or more seals co-operating with the valve stem for regulating discharge of a fluid; wherein the valve further comprises a sealing gasket (14) for sealing the valve to the dispensing container; wherein the one or more seals is / are formed from an elastomeric composition comprising an ethylene-propylene-diene terpolymer; wherein the sealing gasket is formed from an elastomeric composition comprising an isobutylene polymer or co-polymer thereof; and wherein the container contains a formulation comprising: a propellant comprising HFO-1234ze; salbutamol and / or a salt thereof; and from 1 to 2 wt.% of a monohydric alcohol, based on the total weight of the formulation.